ArticleCancer chemotherapy and pharmacology2026
Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Methotrexate (MTX) is a cornerstone non-surgical therapy for ectopic pregnancy, but its narrow therapeutic window necessitates strict dose verification to prevent toxicity. We report a case of severe MTX intoxication in a 31-year-old woman following salpingostomy, resulting from a dosing error. After receiving an excessive intramuscular dose, the patient developed severe gastrointestinal symptoms and acute kidney injury (AKI). Initial management included prompt leucovorin rescue, urine alkalinization, and intensive supportive care; however, renal dysfunction progressed with impaired MTX clearance. In the absence of glucarpidase, the patient was transferred to the intensive care unit (ICU) and treated with continuous renal replacement therapy (CRRT), which facilitated sustained MTX removal and was followed by gradual clinical and biochemical recovery. This case highlights the critical importance of dose verification in MTX administration and illustrates that, when conventional measures are insufficient and glucarpidase is unavailable, CRRT may serve as a viable salvage therapy for life-threatening MTX toxicity complicated by AKI.
Indexed as
Identifiers
42301427What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.